A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre- S2 particles for revaccination of healthy adult nonresponders

Journal of Infectious Diseases

Volumn 175, Issue 3, 1997, Pages 678-681

  Bertino Jr , Joseph S ^a   Tirrell, Paul ^b   Greenberg, Richard N ^b   Keyserling, Harry L ^b   Poland, Gregory A ^b   Gump, Dieter ^b   Kumar, Mary Lou ^b   Ramsey, Keith ^b  

^a BASSETT HEALTHCARE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FEVER; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INFECTION PREVENTION; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

EID: 0031029869     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/175.3.678     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the united states through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee. MMWR 1991;40(RR-13):1-26.
2. Roome AJ, Walsh SJ, Carter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270:2931-4.
3. Craven DE, Awdeh ZL, Kunches LM, et al. Nonresponsiveness to Hepatitis B vaccine in health care workers. Results of revaccination and genetic typing. Ann Intern Med 1986;105:356-60.
4. Centers for Disease Control and Prevention. Hepatitis surveillance. Atlanta: CDC, 1994; report no. 55.
5. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibodies following hepatitis B vaccination of Minnesota health care workers. JAMA 1993;270:2935-9.
6. Egea E, Iglesias A, Salazar M, et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 1991;173:531-8.
7. West DJ. Clinical experience with hepatitis B vaccines. Am J Infect Control 1989;17:172-80.
8. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315:209-14.
9. Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 1988;260:1734-8.
10. Nagafuchi S, Kashiwagi S, Okada K, et al. Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. JAMA 1991;265:2679-83.
11. Calandra GB, West DJ. Recommendations for prevention of hepatitis B with vaccine. In: Ellis RW, ed. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker, 1993:1-16.
12. Milich DR, McLachlan A, Chisari FV, Kent SB, Thorton GB. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol 1986;137:315-22.
13. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic predictors of nonresponse to hepatitis B vaccine. N Engl J Med 1989;321:708-12.
14. McCombs CC, Leggett A, Ramsey KM, Michalski JP. The association of HLA class II alleles defined by restriction fragment length polymorphisms with responsiveness to hepatitis B vaccine. Vaccine Res 1993;2:105-9.
15. SAS Users Guide: Statistics. Cary, NC: SAS Institute, 1985.